January 14, 2011 -- Chesham, UK - Biopharm Services Ltd (BPS) has appointed an Advisory Board to advance the strategic development of the company, building on the success of its patented BioSolve software that enables biologics manufacturers to ‘test run’ every phase of a drug’s development where typically 80% of cost is incurred.
Biopharm Services has been working with industry since 1999 to address the research and development cost issues associated with biomanufacturing. Biopharm Services is working with the majority of leading biopharmaceutical development and manufacturing sites in the U.S., Europe and now Australia. The appeal of Biopharm’s services has grown steadily with the pressure on health services and providers on both sides of the Atlantic to deliver better value health care to patients.
Andrew Sinclair, President and founder of Biopharm Services, said the company plans to grow its capacity to meet the demands of biopharmaceutical companies whose expenditures in the research phase can hurt competitiveness and keep health care costs high:
“BioPharm Services is committed to providing biopharmaceutical industries with more and better tools to understand where cost can safely be eliminated during the drug development phase and ultimately deliver better value and care to the patient. With this in mind, Biopharm Services has appointed Mr Udo J. Vetter, a leading German pharma industrialist, and Prof. Nigel Titchener Hooker, a leading academic, to advise our Board of Directors on business strategy. Udo J. Vetter has a proven track record in the establishment and growth of start ups and mature companies. Nigel Titchener-Hooker will guide the future technical direction of the company ensuring that BPS continues at the forefront of technology that provides real value to the industry.”
Udo J. Vetter commented:
“Having observed and worked with BPS for many years, I look forward to building the company’s excellent products and services to meet the industry needs of the next decade. Biopharm is well positioned to deliver innovative tools and services that will enable biomanufacturers attain higher productivity and lower costs. “
Nigel Titchener-Hooker commented:
“My goal is to support BPS in the next phase of their development by ensuring that they focus on and exploit leading-edge technologies. I look forward to the challenge of shaping new versions of BPS BioSolve Suite, and to helping new and future clients get full utility from the company’s tools through active collaboration, research links and training opportunities.
Background
Andrew Sinclair, President and founder Biopharm Services which was established in 1999. He has held a number of senior management positions, prior to Biopharm Services Andrew was director of Engineering and Logistics at Lonza Biologics. Andrew has over 25 year experience in the biopharmaceutical industry working for manufacturing operations (Lonza, Eli Lilly, GlaxoSmithKline) and contractors (Kvaerner, Jacobs engineering). He has been responsible for design, building and operation of biomanufacturing facilities. On a professional level Mr. Sinclair has an MSc in Biochemical Engineering, a Fellow of the Institution of Chemical Engineers he lectures at University College London’s Advanced Centre for Biochemical Engineering where he is a Principal Visiting MBI Lecturer.
Miriam Monge an experienced marketing professional has over 20 years experience in the biopharmaceutical sector. Prior to joining BPS Miriam was Marketing Director at Sartorius Stedim Biotech and was instrumental in creating the market for disposable technologies developing Stedim into the market leader over a 14 year period. Miriam was supported by Biopharm Services to develop a holistic design and implementation approach for disposable technologies. Miriam is the Vice President Marketing & Global Key accounts; joining in 2008 she is helping to transform Biopharm into a major player in the biopharm market. Her first experience in the industry was with the medical devices division of CarnaudMetalbox based in France and Germany. Miriam has published extensively and sits on a number of major industry committees, she is a Senior Visiting lecturer at MBI continuous education biomanufacturing training courses, University College London.
Udo J. Vetter is a General Partner of UV-Cap GmbH & Co. KG, Ravensburg, Germany. Mr. Vetter serves as Chairman of the Board of Vetter Pharma Fertigung GmbH & Co. KG, Ravensburg and as Chairman of the Supervisory Board of ITM AG, Munich, of the Advisory Board of Paschal India Ltd., and of Atoll GmbH, Weingarten, He has been a Member of the Supervisory Board of Gerresheimer Holdings GmbH since May 2007 and its subsidiary, Gerresheimer AG, Düsseldorf, since May 14, 2007. He serves as a Member of the Supervisory Board of SeaLionPharma Pte, Singapore, and Gland Pharma Pte. Ltd., Hyderabad, India. He is Member of the Advisory Board of Landesbank Baden-Wuerttemberg.
Nigel Titchener-Hooker is Professor of Biochemical Engineering, Head of Department, Director of The Advanced Centre for Biochemical Engineering, Director of the EPSRC Innovative Manufacturing Research Centre (IMRC) for Bioprocessing. This involves a multidisciplinary group from over twenty departments and a consortium of 15 international companies to research new methods to speed the development of efficient and robust processes for the manufacture of the next generations of macromolecular drugs. A major focus of Nigel’s work is the creation of whole bioprocess models and the use of these to gain process insights and understanding. With colleagues at UCL, Nigel has pioneered studies of decisional tools addressing the interface between bioprocessing and business issues. Nigel is a Fellow of the Royal Academy of Engineering and also a Fellow of the Institution of Chemical Engineers where he also serves on their membership committee
Press Contact: Miriam Monge, Tel: +33 960 365 570, e-mail: m.monge@biopharmservices.com, www.biopharmservices.com
